MedPath

Metformin Versus Insulin in Gestational Diabetes

Phase 4
Completed
Conditions
Gestational Diabetes
Interventions
Registration Number
NCT01240785
Lead Sponsor
Turku University Hospital
Brief Summary

Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. The investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. The investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications).

Detailed Description

Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. The investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. The investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications). The study was performed as a randomized controlled trial in one center, Turku University hospital using the non-inferiority design in June 2006 - December 2010. The final study population consisted of altogether 217 women, of whom 110 received metformin and 107 insulin.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
221
Inclusion Criteria
  • Mothers with gestational diabetes who had at least twice plasma glucose at fasting > 5.4 mmol/L and/or 1 hour postprandial value > 7.7 mmol/L at 24 to 32 gestational weeks
Exclusion Criteria
  1. Fasting glucose > 7.0 mmol/L or 1 hour postprandial plasma glucose > 11.0 mmol/L or Glycosylated hemoglobin A1c (HbA1c) > 7.0%
  2. Renal, hepatic or cardiac failure
  3. Pregestational use of metformin
  4. Pregnancy with multiple fetuses

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
insulininsulinNPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
MetforminmetforminMetformin 500 mg 1-2 tablets twice daily according to plasma glucose values
Primary Outcome Measures
NameTimeMethod
Birth Weight Per Armdelivery

birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies

Secondary Outcome Measures
NameTimeMethod
Pregnancy Induced Hypertension Per Armup to on the average 40 weeks of gestation

Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure \> 30 mmHg or diastolic blood pressure \> 15 mmHg

Maternal Weight Gain Per Armup to on the average 40 weeks of gestation
Pre-eclampsia Per Armup to on the average 40 weeks of gestation
Mode of Delivery Per Armdelivery
Gestational Weeks at Delivery Per Armdelivery
Induction of Delivery Per Armdelivery
Shoulder Dystocia Per Armdelivery
Neonatal Hypoglycemia Per Arm0-24 h after delivery
Neonatal Hyperbilirubinemia Per Arm0-3 days after delivery
Apgar Score at 5 Min After Delivery Per Arm5 minutes after delivery

Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome

Neonate Transfer to Intensive Care Unit Per Arm0-5 days after delivery
Child Outcome at 2 Years Per Arm2 years after birth

neuropsychological and motor skills testing

© Copyright 2025. All Rights Reserved by MedPath